Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...

Please provide your email address to receive an email when new articles are posted on . Patients with type 2 diabetes on metformin had greater HbA1c and blood pressure reductions and lost more weight ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion on a combined product for type 2 diabetes containing empagliflozin and ...

SYNJARDY approval was based on multiple clinical trials showing reductions in blood glucose versus placebo RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 27, 2015 /PRNewswire/ -- The U.S. Food and Drug ...

Data presented at the American Diabetes Association 73rd Scientific Sessions® also show statistically significant reductions in mean daily glucose and body weight in people with type 2 diabetes ...

Positive opinion for a new single-pill combination therapy for adults with type 2 diabetes Empagliflozin when added to metformin HCl lowers blood glucose, body weight and blood pressure Side effects ...

HealthDay News — After metformin failure, sequential treatment escalation with empagliflozin and linagliptin is an effective diabetes treatment option due to additive effects on postprandial glucose ...

Metformin is recommended as a first-line pharmacotherapy for patients with type 2 diabetes, but many patients require add-on therapy. Because of the complementary mechanisms of action of SGLT2 ...

Two empagliflozin-containing treatments were FDA approved for pediatric type 2 diabetes, the agency announced on Tuesday. Once-daily empagliflozin (Jardiance) and empagliflozin/metformin hydrochloride ...

The EMPA-REG OUTCOME trial is part of the new wave of cardiovascular (CV) outcome trials required by the US Food and Drug Administration (FDA) for all new diabetes drugs. Empagliflozin is in the ...

(HealthDay News) — After metformin failure, sequential treatment escalation with empagliflozin and linagliptin is an effective diabetes treatment option due to additive effects on postprandial glucose ...